Neurokinin 1 Receptor (NK1) |
(2 S,3 S)-N-[[2-[11C]Methoxy-5-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]methyl]-2-phenyl-piperidin-3-amine |
[11C]GR205171
|
|
Serotonin transpoter (SERT) |
[11C]2-(2-(Dimethylaminomethyl)phenylthio)-5-fluoromethylphenylamine |
[11C]AFM |
↓SERT availability in MDD218
|
|
[11C]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-
benzonitrile |
[11C]DASB |
↓SERT availability in MDD219,220
|
Serotonin 1B receptor (5HT1B) |
(R-1-[4-(2-methoxy-isopropyl)-phenyl]-3-[2-(4-methyl-piperazin-1-yl)benzyl]-pyrrolidin-2-one) |
[11C]P943 |
↓5HT1B in trauma exposed HC50
|
Serotonin 1A receptor (5HT1A) |
carbon11–labeledN-(2-(1-(4-(2-methoxyphenyl)-1piperazinyl)ethyl))-
N-(2-pyridyl)- cyclohexanecarboxamide |
[carbonyl-C-11]WAY-100635 |
↑5HT1A availability in MDD221
|
|
(N-{2-[4-(2-methoxyphenyl)piperazino]}-N-(2-pyridinyl)trans-4-fluorocyclohexanecarboxamide) |
[18F]CWAY |
No differences in 5HT1A availability in MDD222
|
Dopamine transporter (DAT) |
((99 m)Tc-[2[[2-[[[3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3,2,1]-oct-2-yl]-methyl](2-mercaptoethyl)
amino]ethyl]amino]ethane-thiolato(3-)-N2,N2′,S2,S2]oxo-[1R-(exo-exo)])) |
[99mTC]-TRODAT-1 |
↑DAT availability in PTSD223
|
GABAA-BZR |
[123I]iomazenil |
|
↑ GABAA-BZR availability in PTSD224
|
|
[11C]flumazenil |
|
↑ GABAA-BZR availability in PTSD225
|
Cannabinoid receptor 1 (CB1) |
([11C]JHU75528) |
[11C]OMAR |
↑CB1 availability in PTSD226,227
|
Norepinephrine Transporter (NET) |
[11C]methylreboxetine |
([11C]MRB) |
↓NET availability in PTSD relative to HC, but not trauma
controls228
|
ß2*-nAChR |
(123I-5-IA;
[123I]-5-iodo-3-[2(S)-azetidinylmethoxy]pyridine) |
[123I]5-IA-85380 ([123I]5-IA) |
↑ ß2*-nAChR availability in PTSD229
|
K- Opioid Receptor |
|
[11C]LY2795050 |
↓KOR availability associated with severity of loss symptoms in trauma
survivors |